Fake doctors, misleading claims drive OxyContin China sales



This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

SHANGHAI (AP) — The Sackler family’s opioid empire in the United States is collapsing under an avalanche of litigation over marketing tactics that has driven their company, Purdue Pharma, into bankruptcy.

Meanwhile, the family continues to profit from sales of their signature painkiller OxyContin abroad.

Interviews and documents obtained by AP show their international affiliate, Mundipharma, has been driving growth in China using many of the same tactics that Purdue was forced to abandon in the U.S. as the death toll from opioid overdoses soared.

Mundipharma aggressively pushed high doses of opioids in China, despite warnings that higher doses carry higher risks of overdose and death.

Mundipharma sales representatives said managers required them to copy patients’ private medical records without consent to better target sales, in apparent violation of Chinese law.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Erika Kinetz

    SIGN UP FOR THE KSL.COM NEWSLETTER

    Catch up on the top news and features from KSL.com, sent weekly.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast